Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma

Xing, Hao ¹Yan, Cunling ²Cheng, Liming ³Wang, Nianyue ⁴Dai, Shuyang ¹Yuan, Jianyong ¹Lu, Wenfeng ¹Wang, Zhouchong ¹Han, Jun ¹Zheng, Yijie ⁵Yang, Tian¹

扫码查看

作者信息

1. Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg, Shanghai 200438, Peoples R
2. Peking Univ, Hosp 1, Dept Clin Lab, Beijing, Peoples R China
3. Huazhong Univ Sci & Technol, Tongji Hosp, Dept Clin Lab, Wuhan, Peoples R China
4. Southeast Univ, Sch Med, Hosp Nanjing 2, Nanjing, Jiangsu, Peoples R China
5. Abbott Diagnost, Med Sci Affairs, Shanghai 200003, Peoples R China
折叠

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. Early diagnosis improves the prognosis. Protein induced by vitamin K antagonist-II (PIVKA-II) is an effective serum biomarker for HCC diagnosis and prognosis. Combined with another serum biomarker alpha-fetoprotein (AFP), the sensitivity and specificity of HCC diagnosis can be improved to a maximum of 94 and 98.5 %, respectively. PIVKA-II alone or in combination with AFP and/or AFP-L3 was effective in predicting the treatment response and clinical outcome of curative hepatic resection, chemotherapy, targeted therapy, radiotherapy, and liver transplantation. Japanese clinical guidelines recommend the combined use of PIVKA-II and AFP for the diagnosis of HCC, management of high-risk population, and prognosis of anticancer treatment. Further, PIVKA-II as a functional target promoted HCC cell proliferation, invasion, and metastasis by activating c-Met and other signal transduction pathways. Inhibition of PIVKA-II may provide a selective and effective therapy for HCC.

Key words

Protein induced by vitamin K antagonist-II/Biomarker/Hepatocellular carcinoma/Diagnosis/Treatment outcome

引用本文复制引用

出版年

2016

Tumour biology

ISSN：1010-4283

被引量8

参考文献量80

段落导航